A citation-based method for searching scientific literature

Catherine B Meador, Aaron N Hata. Pharmacol Ther 2020
Times Cited: 14







List of co-cited articles
32 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
28


Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
J Jean Cui, Michelle Tran-Dubé, Hong Shen, Mitchell Nambu, Pei-Pei Kung, Mason Pairish, Lei Jia, Jerry Meng, Lee Funk, Iriny Botrous,[...]. J Med Chem 2011
499
21

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
21

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
21

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Paula J Spitzler, Jonathon P Orme, M Raymond V Finlay, Richard A Ward, Martine J Mellor,[...]. Cancer Discov 2014
14

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Narjust Duma, Rafael Santana-Davila, Julian R Molina. Mayo Clin Proc 2019
289
14

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
Tara R Rheault, John C Stellwagen, George M Adjabeng, Keith R Hornberger, Kimberly G Petrov, Alex G Waterson, Scott H Dickerson, Robert A Mook, Sylvie G Laquerre, Alastair J King,[...]. ACS Med Chem Lett 2013
92
14

COSMIC: the Catalogue Of Somatic Mutations In Cancer.
John G Tate, Sally Bamford, Harry C Jubb, Zbyslaw Sondka, David M Beare, Nidhi Bindal, Harry Boutselakis, Charlotte G Cole, Celestino Creatore, Elisabeth Dawson,[...]. Nucleic Acids Res 2019
14

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
J Mazieres, C Cropet, L Montané, F Barlesi, P J Souquet, X Quantin, C Dubos-Arvis, J Otto, L Favier, V Avrillon,[...]. Ann Oncol 2020
40
14

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Dong-Wan Kim, Dae Ho Lee, Ji-Youn Han, Jongseok Lee, Byoung Chul Cho, Jin Hyoung Kang, Ki Hyeong Lee, Eun Kyung Cho, Jin-Soo Kim, Young Joo Min,[...]. Lung Cancer 2019
13
15


CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki. Cancer Cell 2011
428
14

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
14

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
14

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli,[...]. Clin Cancer Res 2012
283
14

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Simon Vyse, Paul H Huang. Signal Transduct Target Ther 2019
98
14

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
14

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang,[...]. Clin Cancer Res 2019
51
14

The biogenesis, biology and characterization of circular RNAs.
Lasse S Kristensen, Maria S Andersen, Lotte V W Stagsted, Karoline K Ebbesen, Thomas B Hansen, Jørgen Kjems. Nat Rev Genet 2019
960
14

Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor.
Yehoshua Enuka, Mattia Lauriola, Morris E Feldman, Aldema Sas-Chen, Igor Ulitsky, Yosef Yarden. Nucleic Acids Res 2016
232
14

Mutation and cancer: statistical study of retinoblastoma.
A G Knudson. Proc Natl Acad Sci U S A 1971
14

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
Nicholas McGranahan, Francesco Favero, Elza C de Bruin, Nicolai Juul Birkbak, Zoltan Szallasi, Charles Swanton. Sci Transl Med 2015
372
14

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Sydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, Eduardo A Torre, Benjamin Emert, Clemens Krepler, Marilda Beqiri, Katrin Sproesser, Patricia A Brafford, Min Xiao,[...]. Nature 2017
432
14

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Sreenath V Sharma, Diana Y Lee, Bihua Li, Margaret P Quinlan, Fumiyuki Takahashi, Shyamala Maheswaran, Ultan McDermott, Nancy Azizian, Lee Zou, Michael A Fischbach,[...]. Cell 2010
14

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Aaron N Hata, Matthew J Niederst, Hannah L Archibald, Maria Gomez-Caraballo, Faria M Siddiqui, Hillary E Mulvey, Yosef E Maruvka, Fei Ji, Hyo-eun C Bhang, Viveksagar Krishnamurthy Radhakrishna,[...]. Nat Med 2016
464
14

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.
Michael Ramirez, Satwik Rajaram, Robert J Steininger, Daria Osipchuk, Maike A Roth, Leanna S Morinishi, Louise Evans, Weiyue Ji, Chien-Hsiang Hsu, Kevin Thurley,[...]. Nat Commun 2016
221
14

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.
Eishu Hirata, Maria Romina Girotti, Amaya Viros, Steven Hooper, Bradley Spencer-Dene, Michiyuki Matsuda, James Larkin, Richard Marais, Erik Sahai. Cancer Cell 2015
315
14

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Khyati N Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Victoria E Wang, Golzar Hemmati, Maria M Martins, Ashley Maynard, Jonathan Kuhn,[...]. Nat Med 2019
97
14

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
14

Neoantigen-directed immune escape in lung cancer evolution.
Rachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, Maise Al Bakir, David A Moore, Crispin T Hiley, Tom Lund, Miljana Tanić, James L Reading, Kroopa Joshi,[...]. Nature 2019
295
14

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
14

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.
Hongyi Li, Yang Yang, Weiqi Hong, Mengyuan Huang, Min Wu, Xia Zhao. Signal Transduct Target Ther 2020
147
7

Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Wei Li, Jonathan Cooper, Lu Zhou, Chenyi Yang, Hediye Erdjument-Bromage, David Zagzag, Matija Snuderl, Marc Ladanyi, C Oliver Hanemann, Pengbo Zhou,[...]. Cancer Cell 2014
144
7

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Camille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, Roger Lacave, Anaïs Pujals, Nicolas Girard, Céline Callens, Valérie Gounant, Nathalie Théou-Anton, Sylvie Friard,[...]. Lung Cancer 2019
27
7

Prostate cancer schemes for androgen escape.
A O Brinkmann, J Trapman. Nat Med 2000
59
7

Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia.
S Horiike, S Yokota, M Nakao, T Iwai, Y Sasai, H Kaneko, M Taniwaki, K Kashima, H Fujii, T Abe,[...]. Leukemia 1997
173
7


Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Yeonjoo Jung, Pora Kim, Yeonhwa Jung, Juhee Keum, Soon-Nam Kim, Yong Soo Choi, In-Gu Do, Jinseon Lee, So-Jung Choi, Sujin Kim,[...]. Genes Chromosomes Cancer 2012
65
7

Targeting the Hedgehog pathway in cancer.
Lee L Rubin, Frederic J de Sauvage. Nat Rev Drug Discov 2006
581
7


Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Anna Li, Jin-Ji Yang, Xu-Chao Zhang, Zhou Zhang, Jian Su, Lan-Ying Gou, Yu Bai, Qing Zhou, Zhenfan Yang, Han Han-Zhang,[...]. Clin Cancer Res 2017
46
7

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Karoline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, Sophia Derdak, Karoline Sonneck, Alexandra Böhm, Alexander Gruze, Puchit Samorapoompichit, Paul W Manley, Doriano Fabbro,[...]. Blood 2006
192
7

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
R Eric Davis, Vu N Ngo, Georg Lenz, Pavel Tolar, Ryan M Young, Paul B Romesser, Holger Kohlhammer, Laurence Lamy, Hong Zhao, Yandan Yang,[...]. Nature 2010
7

Precision Medicine and Targeted Therapies in Breast Cancer.
Ian Greenwalt, Norah Zaza, Shibandri Das, Benjamin D Li. Surg Oncol Clin N Am 2020
11
9


FLT3 inhibitor quizartinib (AC220).
Kiran Naqvi, Farhad Ravandi. Leuk Lymphoma 2019
10
10


Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
232
7

The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma.
Norifumi Harimoto, Kenichi Taguchi, Ken Shirabe, Eisuke Adachi, Yoshihisa Sakaguchi, Yasushi Toh, Takeshi Okamura, Hiroto Kayashima, Akinobu Taketomi, Yoshihiko Maehara. Oncology 2010
35
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.